Table 4 Third-line regimen patient characteristics and early outcomes on third-line ART

Gender

N, %

 Male

31/82 (37.8%)

12/36 (33.3%)

19/46 (41.3%)

 Female

51/82 (62.2%)

24/36 (66.7%)

27/46 (58.7%)

Age, years

Median, IQR

40.0 (35.5–47.3)

40.0 (35.2–46.8)

40.0 (36.2–47.3)

 18–30

N, %

5/82 (6.1%)

4/36 (11.1%)

1/82 (2.2%)

 30–45

52/82 (63.4%)

20/36 (55.6%)

32/82 (69.6%)

 ≥ 45

25/82 (30.5%)

12/36 (33.3%)

13/82 (28.3%)

CD4 count closest to start of third-line ART, cells/mm³

Median, IQR

N, %

277.0 (194.0–439.0)

263.0 (156.0–390.0)

339.0 (212.0–472.0)

 < 100

9/58 (15.5%)

5/27 (18.5%)

4/31 (12.9%)

 100–200

6/58 (13.7%)

3/27 (11.1%)

3/31 (9.7%)

 200–350

21/58 (32.9%)

12/27 (44.4%)

9/31 (29.0%)

 ≥ 350

22/58 (35.6%)

7/27 (25.9%)

15/31 (48.4%)

 Missing

24/82

9/36

15/46

Third-line regimen

N, %

 DRV/r + RAL + ETV

0/82 (0.0%)

0/36 (0.0%)

0/46 (0.0%)

 DRV/r + RAL

17/82 (20.7%)

11/36 (30.6%)

6/46 (13.0%)

 RAL + ETV

0/82 (0.0%)

0/36 (0.0%)

0/46 (0.0%)

 DRV/r + ETV

5/82 (6.1%)

2/36 (5.6%)

3/46 (6.5%)

 DRV/r

30/82 (36.6%)

12/36 (33.3%)

18/46 (39.1%)

 RAL

18/82 (22.0%)

4/36 (11.1%)

14/46 (30.4%)

 ETV

12/82 (14.6%)

7/36 (19.4%)

5/46 (10.9%)

NRTI backbone

 TDF

31/82 (37.8%)

13/36 (36.1%)

18/46 (39.1%)

 AZT

4/82 (4.9%)

1/36 (2.8%)

3/46 (6.5%)

 ABC

0/82 (0.0%)

0/36 (0.0%)

0/46 (0.0%)

 TDF + AZT

5/82 (6.1%)

4/36 (11.1%)

1/46 (2.2%)

 TDF + ABC

0/82 (0.0%)

0/36 (0.0%)

0/46 (0.0%)

 Other

42/82 (51.2%)

18/36 (50.0%)

24/46 (52.2%)

Viral load closest to start of third-line ART, copies/mL (> 400 copies/mL)

Median, IQR

N, %

13,930.0 (2655.0–62,515.0)

24,096.5 (3877.5–84,934.0)

7883.0 (1504.0–41,485.0)

 < 1000

11/73 (15.1%)

3/36 (8.3%)

8/37 (21.6%)

 1000–50,000

40/73 (54.8%)

20/36 (55.6%)

20/37 (54.1%)

 ≥ 50,000

22/73 (30.1%)

13/36 (36.1%)

9/37 (24.3%)

 Missing

9/82

0/36

9/46

Year starting third-line ART

N, %

 2012

20/82 (24.4%)

3/36 (8.3%)

17/46 (37.0%)

 2013–2016

62/82 (75.6%)

33/36 (91.7%)

29/46 (63.0%)

Time to first ever viral suppression on third-line

N, %

 1–6 months

49/82 (59.8%)

22/36 (61.1%)

27/46 (58.7%)

 6–12 months

16/82 (19.5%)

7/36 (19.4%)

9/46 (19.6%)

 Missing

17/82 (20.7%)

7/36 (19.4%)

10/61 (21.7%)

Outcomes on third-line ART

 Viral suppression on third-line by first viral load within 6 months (early suppression)

N, %

  Alive, in care and suppressed

47/82 (57.3%)

20/36 (55.6%)

27/46 (58.7%)

  Alive, in care and not suppressed

13/82 (15.9%)

7/36 (19.4%)

6/46 (13.0%)

  Alive, in care and no repeat viral load/no repeat viral load within follow-up

17/82 (20.7%)

7/36 (19.4%)

10/46 (21.7%)

Not alive or in care

 Died

2/82 (2.4%)

1/36 (2.8%)

1/46 (2.2%)

 Loss to follow-up*

0/82 (0.0%)

0/36 (0.0%)

0/46 (0.0%)

 Transfer-out

3/82 (3.7%)

1/36 (2.8%)

2/46 (4.4%)

Viral suppression on third-line by 12 months

N, %

 Alive, in care and suppressed

35/82 (42.7%)

16/36 (44.4%)

19/46 (41.3%)

 Alive, in care and not suppressed

7/82 (8.5%)

5/36 (13.9%)

2/46 (4.4%)

 Alive, in care and no repeat viral load/no repeat viral load within follow-up

30/82 (36.6%)

12/36 (33.3%)

18/46 (39.1%)

Not alive or in care

 Died

4/82 (4.9%)

2/36 (5.6%)

2/46 (4.4%)

 Loss to follow-up*

1/82 (1.2%)

0/36 (0.0%)

1/46 (2.2%)

 Transfer-out

5/82 (6.1%)

1/36 (2.8%)

4/46 (8.7%)

Never suppressed viral load below 400 copies/mL by 12 months

N, %

6/71 (8.5%)

4/33 (12.1%)

2/38 (5.3%)